The 37-year-old owner of a bar in Hannam-dong, Seoul, has recently noticed a sharper jawline and flatter stomach. After using ...

An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, ...

Retatrutide by Eli Lilly is a once-weekly medicine that can lower food intake, improve glucose control, and increase calorie burning.

The latest clinical trial results for retatrutide suggest this experimental drug could help adults with obesity shed more ...

Obesity does not just enlarge fat stores, it appears to rework the body’s wiring and immune landscape in ways scientists have ...

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from ...

NEW YORK >> Eli Lilly said today its experimental obesity drug helped patients lose more than 28% of their weight over a year and a half in a key trial that allows the company to seek regulatory ...

Emerging evidence suggests that leptin, dysbiosis, and altered innate immunity may contribute to poor asthma control in ...

New research suggests obesity may leave a long-lasting “memory” on the immune system, even years after weight loss.

An experimental weight loss drug tested in mice targets five receptor systems and may reduce side effects, according to a ...

Collecting BMI data could further research into why women with lung cancer have better survival outcomes than men.An ...

NEW YORK, May 21 (Reuters) - Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a key ...